Profusa
Profusa, Inc. (Nasdaq: PFSA) is a South San Francisco digital-health and medical-device company that builds tissue-integrated biosensors — injectable, biologically compatible hydrogel microsensors smaller than a grain of rice — for continuous, real-time monitoring of body chemistry. Its Lumee Oxygen Platform reports tissue oxygen for peripheral artery disease, chronic wounds and reconstructive surgery, and a long-duration Lumee glucose sensor is in development. A companion Data Platform turns raw sensor readings into clinical intelligence for clinicians, with EMR integration described as planned rather than shipped. Profusa has received more than USD 23M in NIH and DARPA funding and became publicly traded in July 2025 through a business combination with NorthView Acquisition Corporation. As of this profiling pass the company publishes no developer program, no public API documentation and no machine-readable API contract.
Profusa is profiled on the APIs.io network. Tagged areas include Company, Health, Medical Devices, Biosensors, and Digital Health.
Profusa’s developer surface includes support, engineering blog, and 8 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Company 7
The organization behind the API
Scroll for all 7
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.